Studies at Mayo Clinic show that oral administration of a monoclonal microbial suppresses multiple sclerosis and rheumatoid arthritis in animal models through modulation of systemic immune responses.
In the published studies, the monoclonal microbial, an anaerobic commensal microbe isolated from a human biopsy sample, led to a decrease in activity of Th17 inflammatory cells and an increase in the activity and frequency of regulatory T-cells.
Under the terms of the agreement, Evelo has a worldwide license to the technology and patent estate developed at Mayo Clinic, including multiple issued patents covering compositions and methods of use.
The data produced at Mayo and supported by Evelo's proprietary platform technologies has enabled a rapid drug development timeline with the first product candidate entering the clinic in 2018.
Revenue that Mayo Clinic receives from the development and commercialization of monoclonal microbials will be used to support its not-for-profit mission in patient care, education, and research.
Evelo Biosciences is developing monoclonal microbials, orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut, and that are broadly applicable across many diseases including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases, and cancer.
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study